Company: PSTV
Filing Date: 2025-08-04
Form Type: DRS
Source: 0000950123-25-006916
Chunk: 32

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-08-04
Form: DRS
Chunk 32
---
 shares of common stock are fully paid and nonassessable, and the shares of common stock offered, when issued, will be fully paid and nonassessable. Preferred Stock We are authorized to issue 5,000,000 shares of preferred stock, 1,952 shares of which were issued and outstanding as of July 30, 2025. Of this amount, there were 938 outstanding shares of Series C Preferred Stock that can be converted into an aggregate of 27,792 shares of common stock, and 1,014 shares of Series B Convertible Preferred Stock that can be converted into an aggregate of 398 shares of common stock. We may issue additional shares of preferred stock, in series, with such designations, powers, preferences and other rights and qualifications, limitations or restrictions as our board of directors may authorize, without further action by our stockholders, including:

| • |     | the distinctive designation of each series and the number of shares that will constitute the series; |

| • |     | the voting rights, if any, of shares of the series and the terms and conditions of the voting rights; |

| • |     | the dividend rate on the shares of the series, the dates on which dividends are payable, any restriction,                                                   
 limitation or condition upon the payment of dividends, whether dividends will be cumulative, and the dates from and after which dividends shall accumulate; |

| • |     | the prices at which, and the terms and conditions on which, the shares of the series may be redeemed, if the 
 shares are redeemable;                                                                                       |

| • |     | the terms and conditions of a sinking or purchase fund for the purchase or redemption of shares of the series, if 
 such a fund is provided;                                                                                          |

| • |     | any preferential amount payable upon shares of the series in the event of the liquidation, dissolution or winding 
 up of, or upon the distribution of any of our assets; and                                                         |

20

Confidential Treatment Requested by Plus Therapeutics, Inc. Pursuant to 17 C.F.R. Section 200.83

| • |     | the prices or rates of conversion or exchange at which, and the terms and conditions on which, the shares of the 
 series may be converted or exchanged into other securities, if the shares are convertible or exchangeable.       |

The particular terms of any additional series of preferred stock, and the transfer agent and registrar for that series, will be described in a prospectus supplement